Iroquois homeobox gene 5 (Irx5) is a highly conserved member of the Iroquois homeobox gene family. Members of this family play distinct and overlapping roles in normal embryonic cell patterning and development of malignancies. In this study, we observed that IRX5 was abnormally abundant in tongue squamous cell carcinoma (TSCC) tissues and cell lines. We used gain-and loss-of-function methods to --
| INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is ranked sixth among the most common solid cancers worldwide, 1 with approximately 686, 328 new cases per annum. 2 Despite advanced surgical techniques in various combinations with radiation and chemotherapy, the overall 5-year survival rate of HNSCC patients is <50%.
3
Tongue squamous cell carcinoma (TSCC) is a common subtype of HNSCC, which is more biologically aggressive than other oral HNSCC cancers. 4 Therapeutic target treatment for TSCC has not been currently met. Exploring the precise molecular mechanism and identifying a new therapeutic marker is crucial for the clinical diagnosis and treatment of TSCC.
As a member of the small integrin-binding ligand N-link glycoprotein (SIBLING) gene family, 5 osteopontin (OPN) is an essential regulator of tumour progression, which was elevated in multiple human malignancies development. [5] [6] [7] OPN plasma levels also act as a potential prognostic factor for tumour relapse and survival. 8, 9 Gu et al reported that OPN knockdown decreased colorectal cancer metastasis both in vivo and in vitro. 10 In HNSCC, the hypoxia signals significantly increased OPN expression, which enhanced cancer angiogenesis, growth and metastasis. 11 Bioinformatics analysis Liyuan Huang and Fangfang Song equally contributed to this study.
----------------------------------------------------------------------------------------------------------------------------------------------------------------------
indicates that the promoter of OPN gene contains potential transcriptional binding sites for Iroquois homeobox 5 (Irx5), suggesting that IRX5 might be a promising mediatory factor affecting OPN gene expression.
Irx genes encode a family of transcription factor with an extremely conserved homeobox domain and a 13 amino-acid characteristic Iroquois domain. 12 The Iroquois family contains 6 genes in mice and humans, which are organized into two cognate clusters, IrxA (Irx1, Irx2 and Irx4) and IrxB (Irx3, Irx5 and Irx6), and located in two different chromosomes. 13 Irx genes play pivotal roles in cell specification and patterning during development processes, as well as human carcinomas, either as activators or suppressors; 12,14 this dual effect differs in different Irx gene and species. Notably, IRX5 is enhanced in colorectal cancer and human adenomas, 15, 16 and IRX5
silencing inhibited LNCaP prostate cancer cell apoptosis. 17 However, although several studies regarding the connection of IRX5 with cancer have been reported, the accurate functions of IRX5 in the progression and suppression of TSCC remains largely indistinct.
Therefore, the aim of this study was to demonstrate the relationship of IRX5 with TSCC and to examine the potential novel target of IRX5.
In this study, we found that IRX5 was significantly up-regulated in TSCC tissues and cell lines. The expression of IRX5 is associated with TSCC cell proliferation, migration and invasion. Moreover, IRX5
exerts this role through targeting OPN promoter, and NF-jB pathway also participated in this promoting progress.
| MATERIALS AND METHODS

| Ethics approval and consent to participate
All of our experiments were approved by the Institutional Ethical 
| Human tissue specimens
A total of 12 samples of human TSCC tissues and corresponding adjacent normal tongue tissues were used in this study. All patients, from whom the tissue samples were collected, were clinically and histopathologically diagnosed with TSCC at the School and Hospital of Stomatology, Wuhan University, and underwent surgical resection with the approval of the Ethics Committee. The formalin-fixed, paraffin-embedded portions of surgical specimens were subjected to IHC analysis, and the remaining portions were immediately frozen in liquid nitrogen and stored at À80°C in our laboratory. TSCC was histopathologically confirmed, after which the tumour specimens were used to extract mRNA and protein for qRT-PCR and Western blot analysis.
| Cell culture and reagents
Human cell lines (SCC9, SCC25 and CAL27) were purchased from the American Type Culture Collection (ATCC, Manassas, USA) and grown in DMEM (HyClone, South Logan, UT, USA) supplemented with 10% foetal bovine serum (FBS, Gibco, Grand Island, NY, USA), 100 U/mL of penicillin and 100 U/mL of streptomycin. All cell lines were grown at 37°C in 5% CO 2 and air-humidified incubator.
Puromycin dihydrochloride (MDBio, Qingdao, China) was added at 2 lg/mL to screen transfected cells. BAY 11-7082 (Beyotime Biotechnology, Shanghai, China) was used at 3 lmol/L to inhibit the NF-jB signalling pathway (1 mmol/L stock in DMSO).
| Human keratinocytes isolation and culture
Human keratinocytes were isolated from tongue noncancerous disease patients (16- 
| Lentiviral transduction
Human full-length of IRX5 CDS was cloned into an empty pLVX- 
| Transient transfection
siRNAs targeted IRX5 and OPN were synthesized from GenePharma (Suzhou, China). The sequences are listed in Table S2 . Cells were transfected with targeting siRNAs or plasmids using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. IRX5
and OPN expressions were measured using qRT-PCR and Western blot analysis.
| Bioinformatics analyses
Osteopontin candidate promoter sequences from À2000 to +200
were retrieved from NCBI, and analysed using MatInspector software (http://www.genomatix.de/matinspector.html.) for the putative IRX5 binding site.
| Dual luciferase assay
Putative OPN promoter fragment were amplified and the products were cloned into pGL3-basic vector. The primer sequences of OPN promoter were listed in Table S1 . CAL27 cells were plated onto 24-well plate at a density of 1 
| CCK8 assay
Cell suspensions (100 lL) containing 5000 cells were plated on 96-well plate per well. After incubation for the indicated time periods (24, 48, 72 and 96 hours), media were removed and replaced with 100 lL culture media containing 10 lL of CCK8 solution (Beyotime) for 2 hours. The supernatant was collected, and absorbance at 450 nm was measured using a microplate reader to calculate cell growth rate.
| Wound healing assay
CAL27 cells were plated on 6-well plate at a density of 3 9 10 5 cells per well. When the cells reached 95% confluency, a sterile 20 lL pipette tip was used to make a wound scratch, and PBS was used to remove the detached cells. Phase contrast images were collected in the same field at indicated time periods (0, 24, 36 and 48 hours) using an inverted microscope (Leica).
| Transwell assay
Cell migration and invasion assays were conducted using 24-well transwells (8.0-lm pore size) with one-fourth dilution or without matrigel coating (BD, Franklin Lakes, NJ, USA). In total, 1-3 9 10 
| H&E staining and IHC
Paraffin-embedded TSCC tissues and xenograft tumours were sectioned at 5 lm and mounted onto silane-coated slides (Thermo 
| Statistical analysis
All the quantitative parameters were given as mean AE SEM. Comparisons were analysed by Student's t test for 2 groups and ANOVA for more than 2 groups using SPSS version 17.0. P values <.05 were considered significantly different.
| RESULTS
| IRX5 is up-regulated in TSCC tissues and cell lines
We first assayed IRX5 expression pattern in 12 pairs of human TSCC tissues and relevant adjacent normal tongue tissues. Immunological
Histological Chemistry (IHC) analysis demonstrated that IRX5 levels were noticeable higher in TSCC than that in normal tissues ( Figure 1A) . Moreover, IRX5 protein and mRNA levels were also elevated in TSCC than in normal tissues, evidenced by Western blot and qRT-PCR ( Figure 1B,C) . We then evaluated IRX5 protein levels of 3 human TSCC cell lines (SCC9, SCC25 and CAL27) and human normal tongue keratinocytes (KCs). Consistently, IRX5 protein levels were significantly higher in the 3 TSCC cell lines than in normal KCs ( Figure 1D ), and the expression of IRX5 was highest in CAL27.
These results indicated that up-regulated IRX5 expression might be involved in TSCC progression.
| IRX5 overexpression promotes in vitro TSCC cell proliferation, migration and invasion
To reveal whether IRX5 is involved in TSCC progression, we stably overexpressed exogenous IRX5 in CAL27 cells using lentiviral transduction system. IRX5 expression was quantitated by qRT-PCR and
Western blot analyses 48 hours post-infection. IRX5 mRNA and protein levels were enhanced about 300-and 3-fold respectively (Figure 2A,B) . The CCK8 assay revealed that IRX5 overexpression markedly elevated proliferation rate of CAL27 cells ( Figure 2C ).
mRNA levels of the G1 cell cycle control protein (cyclinD1), which has been demonstrated to promote tumorigenicity and growth of HNSCC in vitro and in vivo, 18 were also increased relative to those in control ( Figure 2D ). Furthermore, well-established metastasisassociated wound healing and transwell assays suggested that IRX5 overexpression facilitates migration and invasion capacities of TSCC cells in vitro ( Figure 2E ,F).
| IRX5 knockdown reduces TSCC cell growth, migration and invasion in vitro
Given increased IRX5 expression in TSCC cells, the loss-of-function studies were conducted using CAL27 cells either by stable transduction with two different short hairpin RNAs targeting IRX5 (shIRX5#1, 
| OPN is a target of IRX5
First, we detected OPN expression with respect to various levels of IRX5 expression. Results revealed that overexpressed IRX5 led to elevated OPN mRNA and protein levels ( Figure 4A,B) . Similarly, the knockdown of IRX5 expression concomitantly decreased OPN levels ( Figure 4C-F) . Next, we analysed the OPN promoter for potential IRX5 binding sites. Using Genomatix MatInspector, we found that the human candidate OPN promoter sequence from À2000 to +200 contained one IRX5 binding sites. Furthermore, we hand-screened the OPN promoter sequence from 3 mammalian species for the IRX5 binding sites (ACANNTGT). All OPN promoters contained the IRX5 binding sites (Table S1 ). To confirm that IRX5 directly regulates OPN promoter, dual-luciferase reporter assay was performed. We cloned fragments of the human OPN promoter (between À2284 to À378) to pGL3-basic luciferase plasmid, pGL3-basic luciferase vector was used as control. And then we transfected these two plasmids respectively into the IRX5-overexpressing CAL27 or IRX5-Vector 
| NF-jB pathway activation is involved in IRX5/
OPN-induced TSCC proliferation, migration and invasion
It has been reported that OPN modulates the NF-jB pathway in various cancers. 19, 20 Therefore, we examined whether IRX5 acted as an upstream of OPN/NF-jB. Our results indicated that IRX5 overexpression resulted in increased nuclear p65 level and led to increased IjBa degradation. Furthermore, levels of MMP2, which acts as the downstream of the NF-jB pathway, 21 were also elevated in IRX5 overexpressing cells. Consistent with these results, the knockdown of IRX5 expression using shRNA resulted in decreased nuclear p65, MMP2 expression and IjBa degradation ( Figure 5A ). In addition, Conversely, the knockdown of IRX5 expression suppressed NF-jB luciferase activity ( Figure 5C ). BAY11-7082, a NF-jB signalling pathway inhibitor, 22 decreased IjBa phosphorylation and degradation to block the NF-jB pathway activity ( Figure 5D ). Our results revealed that BAY11-7082 treatment inhibited the proliferation rate of CAL27 cells transfected with either IRX5 or an empty vector ( Figure 5E ). Similarly, BAY 11-7082 stimulation attenuated migration-promoting effect of CAL27-IRX5 cells ( Figure 5F ). We then examined the levels of phosphorylated p65 and MMP2 as well as
IjBa degradation in CAL27-IRX5 cells treated with siOPN#2, and we observed that the previously elevated expression and degradation of the corresponding factors were decreased ( Figure 5G ). These findings suggest that IRX5 regulates TSCC cell proliferation, migration and invasion by promoting the OPN/NF-jB pathway.
| IRX5 promotes TSCC progression in vivo
We finally examined the biological effect of IRX5 on TSCC tumorigenesis in a xenograft mouse model. CAL27 cells transfected with IRX5, empty vector, shIRX5#2, or shNC were subcutaneously injected into nude mice, and tumour volume was recorded every 
| DISCUSSION
Recently, dysregulation of Irx genes has been observed to have functional significance for multiple cancers, which has been reported to play either a promotive role or a repressive role in regulating tumour progression and metastasis. 23, 24 Better knowledge of cancer-related transcription factors is critical for gaining novel mechanical insights into carcinogenesis and clarifying effective therapies for cancers. In normal tissues, IRX5 is involved in various cellular activities, such as cell proliferation, cell specification and vascular remodelling. 25 Meanwhile, these processes may contribute to both cancer progression and maintaining tumour microenvironment during tumour growth and metastasis. However, the association of dysregulated IRX5 and 16 This prompts us that IRX5 may be exploited as a promising therapeutic target for the treatment of TSCC.
15-17
Here we delineated a new regulatory pathway in which IRX5
transcriptionally regulates OPN and thus, impacts cancer progression.
OPN plays a crucial tumour-promotive effect in the occurrence and progression of different cancers. In several types of cancers, the levels of OPN, including the plasma level of OPN, were significantly increased, such as pancreatic ductal adenocarcinoma, 26 prostate cancer. 27 Moreover, plasma levels of OPN has been demonstrated to act as potential prognostic factors for tumour relapse and survival. 28 In HNSCC, OPN enhances tumour angiogenesis, growth and metastasis. 11 Irx genes have been reported to recognize and bind to a palindromic sequence ACANNTGT to transcriptionally regulate target genes. 29 Using MatInspector, we found that there are IRX5 tran- 21 where it degrades the ECM, which is a pivotal step in tumour metastasis and invasion. 31, 32 In our study, MMP2 was up-regulated by IRX5/OPN signalling, which partially explains the promoting effect of IRX5 in TSCC. In addition, NFjB is an important marker in high-risk HNSCC patients and is, therefore, an attractive target for chemoprevention. However, because of several limitations, such as high cost, functional pleiotropy and safety concerns, NF-jB inhibitors have not yet been used in clinical practice. 33 We recommend the use of IRX5 as a novel molecular therapy target for TSCC.
In summary, our study demonstrated that IRX5 is up-regulated in 
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